Latest data on GLP-1 drugs is that a large proportion of users are giving up taking them due to side effects. After all they were not designed for weight loss but to treat a serious disease and I suspect people with this disease will accept some side effects more than a healthy but over weight person. Therefore short term, GLP-1 drugs may start to lose their attractiveness but my core opinion remains unchanged - longer-term there are better weight loss drugs on the way and this will impact RMD. Remember RMD is a very specialized business. A strength and a weakness.
Buy RMD now and get great upside returns in a year or two, page-80
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$37.39 |
Change
0.390(1.05%) |
Mkt cap ! $22.84B | |||
| Open | High | Low | Value | Volume |
| $37.30 | $37.39 | $37.07 | $9.729M | 260.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 44 | $37.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $37.39 | 2573 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| RMD (ASX) Chart |